Virtu Financial LLC Ovid Therapeutics Inc. Transaction History

Virtu Financial LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 26, 2024	BUY	$2.98 - $3.78 $72,306 - $91,717	24,264 New	24,264 $78,000
Q1 2023 May 01, 2023	BUY	$1.88 - $2.85 $33,636 - $50,992	17,892 New	17,892 $46,000
Q3 2022 Nov 07, 2022	BUY	$1.84 - $2.26 $19,038 - $23,384	10,347 New	10,347 $19,000
Q1 2021 May 19, 2021	SELL	$2.42 - $4.47 $37,812 - $69,843	-15,625 Closed	0 $0
Q4 2020 Feb 24, 2021	BUY	$2.28 - $6.84 $4,229 - $12,688	1,855 Added 13.47%	15,625 $36,000
Q3 2020 Dec 11, 2020	BUY	$5.39 - $8.24 $74,220 - $113,464	13,770 New	13,770 $79,000
Q2 2020 Aug 07, 2020	SELL	$2.67 - $7.91 $196,274 - $581,472	-73,511 Closed	0 $0
Q4 2019 Feb 04, 2020	BUY	$2.08 - $5.06 $101,639 - $247,256	48,865 Added 198.27%	73,511 $305,000
Q3 2019 Nov 20, 2019	BUY	$1.76 - $3.51 $43,376 - $86,507	24,646 New	24,646 $80,000
Q2 2019 Aug 13, 2019	SELL	$1.59 - $2.14 $16,092 - $21,658	-10,121 Closed	0 $0
Q1 2019 Apr 12, 2019	SELL	$1.77 - $3.56 $5,862 - $11,790	-3,312 Reduced 24.66%	10,121 $18,000
Q1 2018 May 14, 2018	BUY	$6.53 - $9.82 $87,717 - $131,912	13,433 New	13,433 $95,000

39M

37.4K

500

Ticker OVID
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,419,400
Market Cap $73.2M
Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.